世界の前立腺がん治療薬市場予測と分析...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 7
1.1 List of Tables 12
1.2 List of Figures 15
2 Introduction 16
2.1 Catalyst 16
2.2 Upcoming Related Reports 16
3 Disease Overview 17
3.1 Etiology and Pathophysiology 17
3.1.1 Etiology 17
3.1.2 Pathophysiology 17
3.1.3 Prognosis 18
3.1.4 Quality of Life 19
3.2 Symptoms 19
4 Epidemiology 20
4.1 Risk Factors 20
4.2 Global and Historical Trends 21
4.2.1 Prevalence 21
4.2.2 Diagnosed Prevalence 21
4.2.3 Diagnosed Incidence 22
4.2.4 Mortality 23
4.3 Forecast Methodology 24
4.3.1 Forecast Assumptions and Methods 26
4.4 Incident/Prevalent Cases of Prostate Cancer 27
4.4.1 Prevalent Cases of Prostate Cancer 27
4.4.2 Incident Cases of Prostate Cancer 29
4.4.3 Five-Year Relative Survival Rates 30
5 Disease Management 31
5.1 Diagnosis and Referral Overview 31
5.2 Treatment Overview 33
5.2.1 Conservative Management Strategies 37
5.2.2 Localized Treatments 38
5.2.3 Hormone Therapy 39
5.2.4 Drug Therapies 41
5.3 US 42
5.3.1 Diagnosis 42
5.3.2 Clinical Practice 42
5.4 France 44
5.4.1 Diagnosis 44
5.4.2 Clinical Practice 44
5.5 Germany 46
5.5.1 Diagnosis 46
5.5.2 Clinical Practice 46
5.6 Spain 48
5.6.1 Diagnosis 48
5.6.2 Clinical Practice 48
5.7 Italy 50
5.7.1 Diagnosis 50
5.7.2 Clinical Practice 50
5.8 UK 52
5.8.1 Diagnosis 52
5.8.2 Clinical Practice 52
5.9 Japan 54
5.9.1 Diagnosis 54
5.9.2 Clinical Practice 54
5.10 Australia 56
5.10.1 Diagnosis 56
5.10.2 Clinical Practice 56
5.11 Canada 58
5.11.1 Diagnosis 58
5.11.2 Clinical Practice 58
6 Competitive Assessment 60
6.1 Overview 60
6.2 Strategic Competitor Assessment 61
6.3 Product Profiles – Major Brands, Hormone Therapies 64
6.3.1 Zoladex (goserelin acetate) 64
6.3.2 Lupron Depot (leuprolide acetate) 68
6.3.3 Eligard (leuprolide acetate) 73
6.3.4 Trelstar (triptorelin acetate) 78
6.3.5 Firmagon (degarelix) 82
6.3.6 Casodex (bicalutamide) 86
6.4 Product Profiles – Major Brands, Chemotherapies 91
6.4.1 Taxotere (docetaxel) 91
6.4.2 Jevtana (cabazitaxel) 95
6.5 Product Profiles – Major Brands, Therapeutic Vaccines 100
6.5.1 Provenge (sipuleucil-T) 100
6.6 Product Profiles – Major Brands, Targeted Therapies 106
6.6.1 Zytiga (abiraterone acetate) 106
6.6.2 Xtandi (enzalutamide) 111
6.7 Product Profiles – Major Brands, Bone Therapies 116
6.7.1 Xgeva (denosumab) 116
6.7.2 Zometa (zoledronic acid) 120
6.8 Other Marketed Hormone and Drug Therapies 124
7 Opportunity and Unmet Need 125
7.1 Overview 125
7.2 Efficacy at Prolonging Overall Survival 126
7.3 Safety 126
7.4 Mitigation of Symptoms 127
7.5 Cost 127
7.6 Convenient Routes of Administration 127
7.7 Accurate Diagnostic Tests and Surveillance Tools 128
7.8 Unmet Needs Gap Analysis 128
7.9 Opportunity: Targeting Early-Stage, Hormone-Sensitive Prostate Cancer 130
8 Pipeline Assessment 131
8.1 Overview 131
8.2 Clinical Trial Mapping 132
8.2.1 Clinical Trials by Country 132
8.3 Clinical Trials by Phase and Trial Status 133
8.4 Promising Drugs in Clinical Development 134
8.4.1 Cabozantinib 136
8.4.2 Custirsen Sodium 141
8.4.3 Sprycel (dasatinib) 146
8.4.4 Yervoy (ipilimumab) 151
8.4.5 Orteronel 157
8.4.6 Alpharadin (radium-223 chloride) 162
8.4.7 Tasquinimod 167
8.4.8 ProstVac (Vaccinia-PSA-TRICOM/Fowlpox-PSA-TRICOM) 172
9 Current and Future Players 178
9.1 Overview 178
9.2 Trends in Corporate Strategy 179
9.3 Company Profiles 181
9.3.1 AstraZeneca 181
9.3.2 Abbott 184
9.3.3 Sanofi 186
9.3.4 Johnson & Johnson 188
9.3.5 Astellas Pharma 190
10 Market Outlook 193
10.1 Global Markets 193
10.1.1 Forecast 193
10.1.2 Drivers and Barriers – Global Issues 197
10.2 United States 201
10.2.1 Forecast 201
10.2.2 Key Events 204
10.2.3 Drivers and Barriers 204
10.3 France 207
10.3.1 Forecast 207
10.3.2 Key Events 210
10.3.3 Drivers and Barriers 211
10.4 Germany 212
10.4.1 Forecast 212
10.4.2 Key Events 215
10.4.3 Drivers and Barriers 215
10.5 Italy 217
10.5.1 Forecast 217
10.5.2 Key Events 221
10.5.3 Drivers and Barriers 221
10.6 Spain 223
10.6.1 Forecast 223
10.6.2 Key Events 226
10.6.3 Drivers and Barriers 226
10.7 United Kingdom 228
10.7.1 Forecast 228
10.7.2 Key Events 231
10.7.3 Drivers and Barriers 231
10.8 Japan 234
10.8.1 Forecast 234
10.8.2 Key Events 237
10.8.3 Drivers and Barriers 237
10.9 Australia 240
10.9.1 Forecast 240
10.9.2 Key Events 243
10.9.3 Drivers and Barriers 243
10.10 Canada 246
10.10.1 Forecast 246
10.10.2 Key Events 249
10.10.3 Drivers and Barriers 249
11 Appendix 251
11.1 Bibliography 251
11.2 Abbreviations 264
11.3 Methodology 267
11.4 Forecasting Methodology 267
11.4.1 Number of Prostate Cancer Patients Currently Seeking Treatment 267
11.4.2 Percent Drug-treated Patients 268
11.4.3 Percent Hormone Therapy-Treated Patients 268
11.4.4 Drugs Included in Each Therapeutic Class 268
11.4.5 Launch, Patent and Market Exclusivity Expiry Dates 269
11.4.6 General Pricing Assumptions 270
11.4.7 Individual Drug Assumptions 272
11.4.8 Generic Erosion 283
11.4.9 Pricing of Pipeline Agents 283
11.5 Physicians and Specialists Included in This Study 284
11.6 Survey of Prescribing Physicians 285
11.7 About the Authors 286
11.7.1 Authors 286
11.7.2 Global Head of Healthcare 287
11.8 About GlobalData 288
11.9 Contact Us 288
11.10 Disclaimer 288